A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer-Reference-Cited by-同舟云学术

A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer

Published:2021-08-31 Issue:4 Volume:3 Page:226-235
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Oishi Takayuki¹,Sasaki Yuka¹,Tong Ying¹,Chen Lichao¹,Onodera Takae¹,Iwasa Satoru²,Udo Emiko³,Furusato Bungo⁴,Fujimori Hiroaki⁵,Imamichi Shoji¹,Honda Takuya⁶,Bessho Tadayoshi⁷,Fukuoka Junya³,Ashizawa Kazuto⁴,Yanagihara Kazuyoshi⁸,Nakao Kazuhiko⁶,Yamada Yasuhide⁹,Hiraoka Nobuyoshi¹⁰,Masutani Mitsuko¹

Affiliation:

1. Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

2. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

3. Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

4. Cancer Genomics Unit, Clinical Genomics Center, Nagasaki University Hospital, Nagasaki, Japan;

5. Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

6. Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

7. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.

8. Division of Biomarker Discovery, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.

9. Department of Medical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

10. Division of Pathology, National Cancer Center Hospital, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Link

https://www.jstage.jst.go.jp/article/ghm/3/4/3_2021.01001/_pdf

Reference34 articles.

1. 1. Yamada Y, Boku N, Nishina T, et al. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan clinical oncology group trial JCOG9912. Ann Oncol. 2013; 24:2560-2565.

2. 2. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett. 2013; 5:935-942.

3. 3. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994; 94:703-708.

4. 4. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355:983-991.

5. 5. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, Martins RG. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013; 109:2096-2105.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer;BJC Reports;2024-03-05

2. Predictive and prognostic value of excision repair cross-complementing group 1 by multi-omics on the outcomes in patients with advanced gastric cancer;2023-11-26